Caleb Neufeld
Overview
Explore the profile of Caleb Neufeld including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
57
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Srinivasan P, Canova C, Sha S, Nguyen T, Joseph J, Sangerman J, et al.
Biotechnol Bioeng
. 2024 Aug;
121(12):3694-3714.
PMID: 39176568
Recombinant adeno-associated virus (rAAV) is a commonly used in vivo gene therapy vector because of its nonpathogenicity, long-term transgene expression, broad tropism, and ability to transduce both dividing and nondividing...
2.
Destro F, Wu W, Srinivasan P, Joseph J, Bal V, Neufeld C, et al.
Biotechnol Adv
. 2024 Aug;
76:108433.
PMID: 39168354
Current processes for the production of recombinant adeno-associated virus (rAAV) are inadequate to meet the surging demand for rAAV-based gene therapies. This article reviews recent advances that hold the potential...
3.
Yang M, Keumurian F, Neufeld C, Skrip E, Duguid J, Vega-Mercado H, et al.
Adv Physiol Educ
. 2024 May;
48(4):733-741.
PMID: 38813607
Cell therapies have gained prominence as a promising therapeutic modality for treating a range of diseases. Despite the recent clinical successes of cell therapy products, very few formal training programs...
4.
Destro F, Joseph J, Srinivasan P, Kanter J, Neufeld C, Wolfrum J, et al.
Mol Ther Methods Clin Dev
. 2023 Sep;
30:122-146.
PMID: 37746245
Current manufacturing processes for recombinant adeno-associated viruses (rAAVs) have less-than-desired yields and produce significant amounts of empty capsids. The increasing demand and the high cost of goods for rAAV-based gene...
5.
Barone P, Keumurian F, Neufeld C, Koenigsberg A, Kiss R, Leung J, et al.
Biologicals
. 2023 Jan;
81:101661.
PMID: 36621353
The Consortium on Adventitious Agent Contamination in Biomanufacturing (CAACB) collected historical data from 20 biopharmaceutical industry members on their experience with the in vivo adventitious virus test, the in vitro...
6.
Nguyen T, Sha S, Hong M, Maloney A, Barone P, Neufeld C, et al.
Mol Ther Methods Clin Dev
. 2021 Jun;
21:642-655.
PMID: 34095346
Manufacturing of recombinant adeno-associated virus (rAAV) viral vectors remains challenging, with low yields and low full:empty capsid ratios in the harvest. To elucidate the dynamics of recombinant viral production, we...
7.
Sha S, Maloney A, Katsikis G, Nguyen T, Neufeld C, Wolfrum J, et al.
Biotechnol Adv
. 2021 May;
49:107764.
PMID: 33957276
Recombinant adeno-associated viruses (rAAVs) are among the most important vectors for in vivo gene therapies. With the rapid development of gene therapy, current rAAV manufacturing capacity faces a challenge to...
8.
Birkhauser F, Koya R, Neufeld C, Rampersaud E, Lu X, Micewicz E, et al.
J Immunother
. 2013 Feb;
36(2):102-11.
PMID: 23377663
The dendritic cell vaccine DC-Ad-GM·CAIX is an active, specific immunotherapy with the potential of providing a safe and effective therapy against renal cell carcinoma (RCC). Using immunocompetent Balb/c mouse models...